In Vitro: CT52923 inhibit the PDGFRs and stem cell factor receptor with an IC50 value of 100 to 200 nM. CT52923 (0.01-30 μM; 24 h) blocks plateletderived growth factor-induced smooth muscle cell migration or fibroblast proliferation with an IC50 of 64 and 280 nM, respectively.
In Vivo: CT52923 (oral; 5, 15, 30, and 50 mg/kg; twice daily) can significantly inhibit neointima formation following carotid artery injury by oral administration in the rat.